CEL-SCI Corporation (CVM)

$4.22

-0.29 (-6.43%)
Rating:
Recommendation:
Neutral
Symbol CVM
Price $4.22
Beta 1.718
Volume Avg. 0.63M
Market Cap 183.011M
Shares () -
52 Week Range 2.49-12.9
1y Target Est -
DCF Unlevered CVM DCF ->
DCF Levered CVM LDCF ->
ROE -134.76% Strong Sell
ROA -113.55% Strong Sell
Operating Margin -
Debt / Equity 46.89% Neutral
P/E -
P/B 4.70 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CVM news


Mr. Geert Kersten
Healthcare
Biotechnology
American Stock Exchange

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.